Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAnna KalffMLMichael LöwJHJane S. Hocking

Discussion

Loading...

Member takes

Overview

Randomized trial shows no PFS benefit for maintenance therapy in newly diagnosed multiple myeloma, indicating need for caution in treatment.

Key Points

  • To assess the efficacy of low-dose selinexor combined with lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma.
  • Phase III randomized trial
  • Patients underwent 3-6 cycles of VRd induction and ASCT
  • Patients were randomized 1:1 to receive selinexor plus lenalidomide or lenalidomide alone
  • Adverse events and quality of life assessed at multiple time points
  • No significant difference in progression-free survival between treatment groups (p=0.69)
  • Higher complete response rate in combination arm (64% vs. 51%, p=0.056)
  • Increased grade ≥3 adverse events in combination arm (85% vs. 45%, p<0.001)
  • Quality of life scores comparable between both arms
  • Median follow up was 30.1 months for lenalidomide and 28.1 months for selinexor-lenalidomide arm.

Cite This Study

Kalff et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da99https://doi.org/10.1182/blood-2025-4039
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  2. 2Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.2026 · 2 citations
  3. 3The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma2025
  4. 4Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma2026
  5. 5Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study2026